Optimizing Patient Selection and Treatment Sequencing in BCG-Unresponsive NMIBC


Neal Shore, MD, FACS, offers clinical insights on optimizing patient selection and treatment sequencing in BCG-unresponsive NMIBC.

This is a video synopsis/summary of an Investigator Perspectives featuring Neal Shore, MD, FACS.

In concluding remarks on optimizing care, Shore reinforces that BCG remains standard of care for initial treatment of high-risk non–muscle invasive bladder cancer when available. In shortage settings, alternatives like dose-dense gemcitabine plus docetaxel should be considered. Across settings, enrolling patients in clinical trials is critical to advance the field.

For BCG-unresponsive patients, Shore recommends urologic oncologists consider checkpoint inhibitor immunotherapy if comfortable with managing potential immune-related adverse events. Collaboration with medical oncologists is advised given their expertise with these agents. Preventing recurrence and progression remains central to improving patient outcomes and burden of intensive management. Ultimately, Shore conveys excitement for preventing disease advancement in bladder cancer through new therapeutic strategies.

Video synopsis is AI generated and reviewed by Urology Times® editorial staff.

Related Videos
Abstract blur luxury hospital corridor | Image Credit: @ zephyr_p - @ zephyr_p - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.